Pharmacology Research &Perspectives, Volume 12, Issue 4, August 2024.Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecular targeted drugs is useful to avoid drug resistance,
Naoki Okamoto +11 more
wiley +1 more source
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia [PDF]
, 2018 PURPOSE OF REVIEW: Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid leukemia (CP-CML) patients has become a reality. Treatment-free remission (TFR) is the term that identifies success after discontinuation. RECENT
Breccia, Massimo, Foà, Robin
core +1 more source
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse [PDF]
, 2004 Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leukemia. By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular response after imatinib therapy.
Goh, Hyun-Gyung +13 more
core +1 more source
A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia [PDF]
, 2008 Complex variant 9;22 translocations occur in a significant minority of chronic myelogenous leukaemia (CML) patients. Different mechanisms of their formation have been described. We report dual colour dual fusion fluorescence in situ hybridisation data in
Chan, LC, So, CC, Wan, TSK, Yip, SF
core +1 more source
TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
Zdravniški Vestnik, 2004 Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity.
Mateja Grat, Joško Vučkovič
doaj
An imputation method for estimating the learning curve in classification problems [PDF]
arXiv, 2012 The learning curve expresses the error rate of a predictive modeling procedure as a function of the sample size of the training dataset. It typically is a decreasing, convex function with a positive limiting value. An estimate of the learning curve can be used to assess whether a modeling procedure should be expected to become substantially more ...
arxiv
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]
, 2011 The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Elliott, M. +4 more
core +1 more source
Perspectives on the development of a molecularly targeted agent [PDF]
, 2002 STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer.
Druker, Brian J
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2013 Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of
Samuel Roosevelt Campos dos Reis +8 more
doaj +1 more source
The Onset of Mackey-Glass Leukemia at the Edge of Chaos [PDF]
Int. J. Mod. Phys C 12, 1-11 (2001), 2001 In this paper we revisit the Mackey-Glass model for blood-forming process, which was proposed to describe the spontaneous fluctuations of the blood cell counts in normal individuals and the first stage of chronic myelocytic (or granylocytic) leukemia (CML).
arxiv